IN2012MU03359A - - Google Patents

Download PDF

Info

Publication number: IN2012MU03359A
Authority: IN; India
Prior art keywords: oxo; carboxamide; prodrug; thiophene; chloro
Prior art date: 2012-12-26

Application number

Other languages

English (en)

Inventor

Sharadchandra Pradhan Dr Nitin

Sudhir Patil Dr Nilesh

Ramchandra Walavalkar Dr Rajesh

Nilesh Subhash Kulkarni Mr

Sandip Babanrao Pawar Mr

Tarak Sambhaji Pawar Mr

Original Assignee

Wanbury Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-26

Filing date

2013-12-24

Publication date

2015-06-26

2013-12-24 Priority to KR1020157015903A priority Critical patent/KR20150100661A/ko

2013-12-24 Priority to US14/436,018 priority patent/US9359341B2/en

2013-12-24 Priority to AU2013368847A priority patent/AU2013368847B2/en

2013-12-24 Priority to CN201380068642.9A priority patent/CN105431429A/zh

2013-12-24 Priority to IN3359MU2012 priority patent/IN2012MU03359A/en

2013-12-24 Priority to HK16105076.8A priority patent/HK1217101A1/zh

2013-12-24 Priority to PCT/IN2013/000801 priority patent/WO2014102822A2/fr

2013-12-24 Priority to JP2015550211A priority patent/JP2016504348A/ja

2013-12-24 Priority to MX2015003319A priority patent/MX2015003319A/es

2013-12-24 Application filed by Wanbury Ltd filed Critical Wanbury Ltd

2013-12-24 Priority to RU2015112195A priority patent/RU2015112195A/ru

2013-12-24 Priority to CA2883323A priority patent/CA2883323A1/fr

2013-12-24 Priority to BR112015011033A priority patent/BR112015011033A2/pt

2013-12-24 Priority to EP13869179.5A priority patent/EP2897619A4/fr

2015-05-25 Priority to ZA2015/03700A priority patent/ZA201503700B/en

2015-06-26 Publication of IN2012MU03359A publication Critical patent/IN2012MU03359A/en

2015-07-22 Priority to PH12015501625A priority patent/PH12015501625A1/en

2016-05-09 Priority to US15/149,998 priority patent/US20160251342A1/en

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
229940002612 prodrug Drugs 0.000 abstract 2
239000000651 prodrug Substances 0.000 abstract 2
KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
229960001148 rivaroxaban Drugs 0.000 abstract 1
DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 abstract 1
230000009424 thromboembolic effect Effects 0.000 abstract 1
238000011282 treatment Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

IN3359MU2012 2012-12-26 2013-12-24 IN2012MU03359A (fr)

Priority Applications (16)

Application Number	Priority Date	Filing Date	Title
MX2015003319A MX2015003319A (es)	2012-12-26	2013-12-24	Derivado de aldehido de oxazolidinonas sustituidas.
AU2013368847A AU2013368847B2 (en)	2012-12-26	2013-12-24	Aldehyde derivative of substitute oxazolidinones
CN201380068642.9A CN105431429A (zh)	2012-12-26	2013-12-24	取代的噁唑烷酮类的醛衍生物
IN3359MU2012 IN2012MU03359A (fr)	2012-12-26	2013-12-24
HK16105076.8A HK1217101A1 (zh)	2012-12-26	2013-12-24	取代的恶唑烷酮类的醛衍生物
PCT/IN2013/000801 WO2014102822A2 (fr)	2012-12-26	2013-12-24	Dérivé aldéhyde d'oxalidinones substituées
JP2015550211A JP2016504348A (ja)	2012-12-26	2013-12-24	置換オキサゾリジノンのアルデヒド誘導体
KR1020157015903A KR20150100661A (ko)	2012-12-26	2013-12-24	치환된 옥사졸리디논의 알데히드 유도체
RU2015112195A RU2015112195A (ru)	2012-12-26	2013-12-24	Альдегидное производное замещенных оксазолидинонов
US14/436,018 US9359341B2 (en)	2012-12-26	2013-12-24	Aldehyde derivative of substitute oxazolidinones
CA2883323A CA2883323A1 (fr)	2012-12-26	2013-12-24	Derive aldehyde d'oxalidinones substituees
BR112015011033A BR112015011033A2 (pt)	2012-12-26	2013-12-24	derivado aldeído de oxazolidinonas substituídas
EP13869179.5A EP2897619A4 (fr)	2012-12-26	2013-12-24	Dérivé aldéhyde d'oxalidinones substituées
ZA2015/03700A ZA201503700B (en)	2012-12-26	2015-05-25	Aldehyde derivative of substitute oxazolidinones
PH12015501625A PH12015501625A1 (en)	2012-12-26	2015-07-22	Aldehyde derivative of substitute oxazolidinones
US15/149,998 US20160251342A1 (en)	2012-12-26	2016-05-09	Aldehyde derivative of substituted oxazolidinones

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IN3359MU2012 IN2012MU03359A (fr)	2012-12-26	2013-12-24

Publications (1)

Publication Number	Publication Date
IN2012MU03359A true IN2012MU03359A (fr)	2015-06-26

Family

ID=54242230

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN3359MU2012 IN2012MU03359A (fr)	2012-12-26	2013-12-24

Country Status (15)

Country	Link
US (1)	US9359341B2 (fr)
EP (1)	EP2897619A4 (fr)
JP (1)	JP2016504348A (fr)
KR (1)	KR20150100661A (fr)
CN (1)	CN105431429A (fr)
AU (1)	AU2013368847B2 (fr)
BR (1)	BR112015011033A2 (fr)
CA (1)	CA2883323A1 (fr)
HK (1)	HK1217101A1 (fr)
IN (1)	IN2012MU03359A (fr)
MX (1)	MX2015003319A (fr)
PH (1)	PH12015501625A1 (fr)
RU (1)	RU2015112195A (fr)
WO (1)	WO2014102822A2 (fr)
ZA (1)	ZA201503700B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20160251342A1 (en) *	2012-12-26	2016-09-01	Wanbury Ltd.	Aldehyde derivative of substituted oxazolidinones
US9394292B2 (en)	2012-12-26	2016-07-19	Wanbury Ltd.	Rivaroxaban intermediate and preparation thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19962924A1 (de)	1999-12-24	2001-07-05	Bayer Ag	Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) *	2001-06-20	2003-01-02	Bayer Ag	Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de)	2003-01-07	2004-07-15	Bayer Healthcare Ag	Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE102004002044A1 (de)	2004-01-15	2005-08-04	Bayer Healthcare Ag	Herstellverfahren
GT200600196A (es)	2005-05-23	2007-01-15		Compuestos n-formil de hidroxilamina
DE102005045518A1 (de)	2005-09-23	2007-03-29	Bayer Healthcare Ag	2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
WO2007039132A1 (fr)	2005-10-04	2007-04-12	Bayer Healthcare Ag	Nouvelle forme polymorphe et forme amorphe de 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide
DE102006007146A1 (de) *	2006-02-16	2007-08-23	Bayer Healthcare Ag	Aminoacyl-Prodrugs
DE102006039589A1 (de) *	2006-08-24	2008-03-06	Bayer Healthcare Ag	Aminoacyl-Prodrugs II
JP5389028B2 (ja)	2007-08-14	2014-01-15	コンサートファーマシューティカルズインコーポレイテッド	置換オキサゾリジノン誘導体
US7816355B1 (en)	2009-04-28	2010-10-19	Apotex Pharmachem Inc	Processes for the preparation of rivaroxaban and intermediates thereof
ES2905760T3 (es)	2009-07-31	2022-04-12	Krka D D Novo Mesto	Procedimientos para la cristalización del rivaroxabán
EP2521723A1 (fr)	2010-01-04	2012-11-14	Enantia, S.L.	Procédé de préparation de rivaroxaban et ses intermédiaires
EP2354128A1 (fr)	2010-02-10	2011-08-10	Sandoz Ag	Procédé pour la préparation de rivaroxaban
BR112013009531A2 (pt) *	2010-11-11	2016-07-19	Redx Pharma Ltd	derivados de fármaco
EP2697209B1 (fr)	2011-04-11	2015-09-23	Sandoz AG	Procédé de préparation d'oxazolidinones substituées
MD4557C1 (ro)	2011-05-06	2018-10-31	Egis Gyogysszegyar Nyilvanosan Mukodo Reszvenytarsasag	Procedeu de obţinere a rivaroxabanului şi un compus intermediar utilizat în acest procedeu
ES2395304B1 (es)	2011-05-20	2014-01-16	Interquim, S.A.	Procedimiento de obtención de una tiofen-2-carboxamida.
US9394292B2 (en) *	2012-12-26	2016-07-19	Wanbury Ltd.	Rivaroxaban intermediate and preparation thereof

2013
- 2013-12-24 HK HK16105076.8A patent/HK1217101A1/zh unknown
- 2013-12-24 KR KR1020157015903A patent/KR20150100661A/ko not_active Ceased
- 2013-12-24 AU AU2013368847A patent/AU2013368847B2/en not_active Expired - Fee Related
- 2013-12-24 WO PCT/IN2013/000801 patent/WO2014102822A2/fr not_active Ceased
- 2013-12-24 RU RU2015112195A patent/RU2015112195A/ru not_active Application Discontinuation
- 2013-12-24 US US14/436,018 patent/US9359341B2/en not_active Expired - Fee Related
- 2013-12-24 CN CN201380068642.9A patent/CN105431429A/zh active Pending
- 2013-12-24 JP JP2015550211A patent/JP2016504348A/ja active Pending
- 2013-12-24 IN IN3359MU2012 patent/IN2012MU03359A/en unknown
- 2013-12-24 CA CA2883323A patent/CA2883323A1/fr not_active Abandoned
- 2013-12-24 MX MX2015003319A patent/MX2015003319A/es unknown
- 2013-12-24 BR BR112015011033A patent/BR112015011033A2/pt not_active IP Right Cessation
- 2013-12-24 EP EP13869179.5A patent/EP2897619A4/fr not_active Withdrawn
2015
- 2015-05-25 ZA ZA2015/03700A patent/ZA201503700B/en unknown
- 2015-07-22 PH PH12015501625A patent/PH12015501625A1/en unknown

Also Published As

Publication number	Publication date
AU2013368847B2 (en)	2017-03-16
RU2015112195A (ru)	2017-01-31
HK1217101A1 (zh)	2016-12-23
EP2897619A4 (fr)	2016-08-17
AU2013368847A1 (en)	2015-05-28
ZA201503700B (en)	2016-10-26
CA2883323A1 (fr)	2014-07-03
WO2014102822A3 (fr)	2015-10-29
US9359341B2 (en)	2016-06-07
MX2015003319A (es)	2015-08-14
US20150259333A1 (en)	2015-09-17
PH12015501625A1 (en)	2015-09-28
JP2016504348A (ja)	2016-02-12
EP2897619A2 (fr)	2015-07-29
CN105431429A (zh)	2016-03-23
KR20150100661A (ko)	2015-09-02
WO2014102822A2 (fr)	2014-07-03
BR112015011033A2 (pt)	2017-07-11

Publication	Publication Date	Title
ATE545645T1 (de)	2012-03-15	Neue cokristall-verbindung von rivaroxaban und malonsäure
ZA200806891B (en)	2010-02-24	Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders
DK1934208T3 (da)	2011-07-18	Ny polymorf form af 5-chlor-N-({(5S)-2-0x0-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
CR20150001A (es)	2015-02-06	Formas de administración farmacéuticas que comprenden 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil) fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida
EA201391647A1 (ru)	2014-02-28	Способ получения ривароксабана и промежуточные соединения, получаемые в указанном способе
WO2010017948A3 (fr)	2010-04-29	Compositions pharmaceutiques à propriétés de libération modifiées comprenant du 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phényl]-1,3-oxazolidin-5-yl)-méthyl)-2-thiophène carboxamide
MX2009001977A (es)	2009-05-21	Derivados profarmacologicos de aminoacilo y medicamentos para el tratamiento de enfermedades tromboembolicas.
PH12015501625A1 (en)	2015-09-28	Aldehyde derivative of substitute oxazolidinones
WO2012080184A3 (fr)	2012-08-30	Compositions pharmaceutiques liquides administrables par voie orale contenant du 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyle)-phényle]-1,3-oxazolidin-5-yle}-méthyle)-2-thiophène carboxamide
BR112016024825A2 (pt)	2017-08-15	composição contendo rivaroxaban e processo para fabricação de uma composição compreendendo rivaroxaban
IL250168A0 (en)	2017-03-30	Crystalline form of 5 – chloro –n ( { (5s) – 2 – oxo – 3 – [ 4 – ( 5,6 – dihydro – 4h – [ 1,2,4 ] triazin-1-yl) phenyl] – 1, 3-oxazolidine-5-yl}methyl)thiophene-2-an innovative carboxamide and pharmaceutical preparations containing it
CU23445A3 (es)	2009-10-16	Procedimiento de preparación
CU20080051A7 (es)	2009-12-01	Nueva forma polimórfica y la forma amorfa de 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofenocarboxamida